Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Sunitinib malate and exemestane may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth. Giving sunitinib malate and exemestane before
surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be
removed.
PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of
sunitinib malate to see how well it works when given together with exemestane in treating
postmenopausal women with breast cancer.